Multiple Myeloma
Conditions
Brief summary
This study aims to realize an economic evaluation of the introduction of Plerixafor in addition to G-CSF and alternative options, in patients with multiple myeloma (MM) who failed or insufficiently mobilize peripheral blood stem and progenitor cells in response to G-CSF alone.
Interventions
OTHEREconomic evaluation
Sponsors
Institut Paoli-Calmettes
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients diagnosed with Multiple Myeloma who were eligible for high-dose melphalan supported with autologous hematopoietic stem cell transplantation (HSCT) as part of their treatment plan * First mobilization attempt * rhG-CSF alone mobilization regimen * Failed mobilization as documented by an increase in CD34+ cell mobilization deemed insufficient to initiate apheresis (below 15/µL), after the 4 first injections of rhG-CSF that are administered in the evening
Exclusion criteria
* Age \< 18 years; * Primary diagnosis other than MM * 2nd or subsequent mobilization attempt * Patients who previously received HDCT + autologous HSCT * Chemotherapy-based mobilization regimen * Efficient mobilization, allowing for apheresis and collection of the target cell number (5x106 CD34+ cells/kg for every planned autologous transplantation as per institutional SOPs).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cost-effectiveness analysis | 1 year | The cost-effectiveness analysis will be performed using the collection of a transplantable graft as effectiveness criteria; the suitability of collected cell products for transplantation will be judged as per institutional criteria. Direct medical costs will be estimated by micro-costing, i.e. by measuring physical quantities (capital and labor) consumed for each patient and attributing corresponding monetary costs on the basis of average French prices. Costs (including room - inpatient and outpatient, drugs and laboratory tests) will be estimated on the basis of patients' medical records. |
Countries
France
Outcome results
None listed